Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flurbiprofen axetil + palonosetron + pentazocine
- Development stage
- Unknown
- Lead developer
- Helsinn
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of flurbiprofen axetil (a prodrug form of the nonsteroidal anti-inflammatory drug flurbiprofen), palonosetron (a 5-HT3 receptor antagonist), and pentazocine (an opioid analgesic with mixed agonist/antagonist properties). This combination likely targets multiple pain pathways while potentially reducing nausea and vomiting associated with pain management or other procedures.
02
Targets
MOR (Mu opioid receptor)HTR3A (5-hydroxytryptamine receptor 3A)KOR (Kappa opioid receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on flurbiprofen axetil + palonosetron + pentazocine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flurbiprofen axetil + palonosetron + pentazocine.